Document is current
Any future updates will be listed below
-
Authors
Colucci, Fabiana
Avenali, Micol
De Micco, Rosita
Fusar Poli, Marco
Cerri, Silvia
Stanziano, Mario
Bacila, Ana
Cuconato, Giada
Franco, Valentina
Franciotta, Diego
Ghezzi, Cristina
Gastaldi, Matteo
Elia, Antonio Emanuele
Romito, Luigi
Devigili, Grazia
Leta, Valentina
Garavaglia, Barbara
Golfrè Andreasi, Nico
Cazzaniga, Federico
Reale, Chiara
Galandra, Caterina
Germani, Giancarlo
Mitrotti, Pierfrancesco
Ongari, Gerardo
Palmieri, Ilaria
Picascia, Marta
Pichiecchio, Anna
Verri, Mattia
Esposito, Fabrizio
Cirillo, Mario
Di Nardo, Federica
Aloisio, Simone
Siciliano, Mattia
Prioni, Sara
Amami, Paolo
Piacentini, Sylvie
Bruzzone, Maria Grazia
Grisoli, Marina
Moda, Fabio
Eleopra, Roberto
Tessitore, Alessandro
Valente, Enza Maria
Cilia, Roberto https://orcid.org/0000-0002-1990-1939
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05287503 at ClinicalTrials.govnct02914366 at ClinicalTrials.govDocuments that mention this clinical trial
Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in <i>GBA</i>-associated Parkinson’s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol
https://doi.org/10.1136/bmjno-2023-000535
nct02941822 at ClinicalTrials.govDocuments that mention this clinical trial
Management of psychiatric and cognitive complications in Parkinson’s disease
https://doi.org/10.1136/bmj-2021-068718
Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in <i>GBA</i>-associated Parkinson’s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol
https://doi.org/10.1136/bmjno-2023-000535
Use of zebrafish models to investigate rare human disease
https://doi.org/10.1136/jmedgenet-2018-105358
nct02941822 at ClinicalTrials.govDocuments that mention this clinical trial
Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in <i>GBA</i>-associated Parkinson’s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol
https://doi.org/10.1136/bmjno-2023-000535
Use of zebrafish models to investigate rare human disease
https://doi.org/10.1136/jmedgenet-2018-105358
nct05287503 at ClinicalTrials.govDocuments that mention this clinical trial
Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in <i>GBA</i>-associated Parkinson’s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol
https://doi.org/10.1136/bmjno-2023-000535
Use of zebrafish models to investigate rare human disease
https://doi.org/10.1136/jmedgenet-2018-105358
Documents that mention this clinical trial
Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in <i>GBA</i>-associated Parkinson’s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol
https://doi.org/10.1136/bmjno-2023-000535
-
Funding
Funding for this research was provided by:
Italian Ministry of Health (GR-2018-12366771)
Italian Ministry of Health (RRC 2023)
- License Information
